6 Preparation and Use of Adjuvants

Methods in Microbiology

Volumn 25, Issue C, 1998, Pages 471-502

  Lövgren Bengtsson, K ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0013491319     PISSN: 05809517     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0580-9517(08)70690-1     Document Type: Article

References (150)

1. Allison A.C., and Byars N.E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotype and of cell-mediated immunity. J. Immunol. Methods 95 (1986) 157-168
2. Allison A.C., and Byars N.E. Adjuvant formulations and their mode of action. Semin. Immunol. 2 (1990) 369-374
3. Alving C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 140 (1991) 1-13
4. Alving C.R. Immunological aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim. Biophys. Acta 1113 (1992) 307-322
5. Alving C.R. Lipopolysaccaride, lipid A and liposomes containing lipid A as immunologic adjuvants. Immunobiology 187 (1993) 430-446
6. Arend W.P., and Massoni R.J. Characteristics of bacterial lipopolysaccaride induction of interleukin 1 synthesis and secretion by human monocytes. Clin. Exp. Immunol. 64 (1986) 656-664
7. Astiz M.E., Rackow E.C., Still J.G., Howell S.T., Cato A., Von Eschen K.B., Ulrich J.T., Rudbach J.A., McMahon G., and Vargas R. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin. J. Crit. Care Med. 23 (1995) 9-17
8. Azuma I. Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 10 (1992) 1000-1006
9. Barr I.G., and Mitchell G.F. ISCOMs (immunostimulating complexes): the first decade. Immunol. Cell. Biol. 74 (1996) 8-25
10. Bennett B., Check I.J., Olsen M.R., and Hunter R.L. A comparison of commercially available adjuvants for use in research. J. Immunol. Methods 153 (1992) 31-40
11. Bergström-Mollauglu M., Lövgren K., Åkerblom L., Fossum C., and Morein B. Antigen-specific increases in the number of splenocytes expressing MHC class II molecules following restimulation with antigen in various physical forms. Scand. J. Immunol. 36 (1992) 565-574
12. Bloch H. Studies on the virulence of tubercle bacilli: isolation and biological properties of a constituent of virulent organisms. J. Exp. Med. 91 (1950) 197-217
13. Bokhout B.A., van Gaalen C., and Van Der Heijden Ph.J. A selected water-in-oil emulsion; composition and usefulness as an immunological adjuvant. Vet. Immunol. Immunopathol. 2 (1981) 491-500
14. Bomford R. The comparative selectivity of adjuvants for humoral and cell mediated immunity. I. Effect on the antibody response to bovine serum albumin and sheep red blood cells of Freund's incomplete and complete adjuvants, all-hydrogel, Corynebacterium parvum, Bordetella pertussis, muramyldipeptide and saponin. Clin. Exp. Immunol. 39 (1980) 426-434
15. Bomford R. The comparative selectivity of adjuvants for humoral and cell mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pigs, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, allhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyldipeptide and saponin. Clin. Exp. Immunol. 39 (1980) 435-441
16. Bomford R. The adjuvant activity of fatty-acid esters. The role of acyl chain length and degree of saturation. Immunology 44 (1981) 187-192
17. 3 and saponin is related to the immunogenicity of the antigen. Int. Arch. Allergy Appl. Immunol. 75 (1984) 280-281
18. Bomford R., Stapleton M., Winsor S., Beesley J.E., Jessup E.A., Price K.R., and Fenwick G.R. Adjuvanticity and iscom formation by structurally diverse saponins. Vaccine 10 (1992) 572-577
19. Braun D.G., van Hoogevest P., and Schumann G. Muramyl tripeptide-phosphatidylethanolamine: a muramyl dipeptide derivative with lipophilic properties. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 213-237
20. Bretscher P.A., Wei G., Menon J.N., and Bielefeldt-Ohmann H. Establishment of a stable cell-mediated immunity that makes 'susceptible' mice resistant to Leismania major. Science 257 (1992) 539-542
21. Browning M., Reid G.R., Osborne R., and Jarret O. Incorporation of sol- uble antigens into iscoms: HIV gpl20 iscoms induce virus neutralizing antibod- ies. Vaccine 10 (1992) 585-590
22. Brugh M., Stone H.D., and Lupton H.W. Comparison of inactivated Newcastle disease viral vaccines containing different emulsion adjuvants. Am. J. Vet. Res. 44 (1983) 72-75
23. Byars N.E., and Allison A.C. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 5 (1987) 223-228
24. Byars N.E., and Allison A.C. Syntex adjuvant formulation. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 203-212
25. Byars N.E., Allison A.C., Harmon M.W., and Kendall A.P. Enhancement of antibody responses to influenza B virus hemagglutinin by use of a new adju- vant formulation. Vaccine 8 (1990) 49-56
26. Byars N.E., Nakano G., Welch M., Lehman D., and Allison A.C. Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine 9 (1991) 309-318
27. Campbell J.B. Saponins. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 95-127
28. Carozzi S., Salit M., Cantaluppi A., Nasini M.G., Barocci S., Cantarella S., and Lamperi S. Effect of monophosphoryl lipid A on the in vitro function of peritoneal leukocytes from uremic patients on continuous ambulatory peritoneal dialysis. J. Clin. Microbiol. 27 (1989) 1748-1753
29. Chavali S.R., and Campbell J.B. Immunomodulatory effects of orally-administered saponins and nonspecific resistance against rabies infection. Int. Arch. Allergy Appl. Immunol. 84 (1987) 129-134
30. Chedid L., Audibert F., Bona C., Damais C., Parant F., and Parant M. Biological activities of endotoxins detoxified by alkylation. Infect. Immun. 12 (1975) 714-721
31. Chedid L., Parant M., Audibert F., Riveau G., Parant F., Lederer E., Choay J., and Lefrancier P. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect. Immun. 35 (1982) 417-424
32. Cox J., and Coulter A. Advances in adjuvant technology and application. In: Yong W.K. (Ed). Animal Parasite Control Utilizing Biotechnology (1992), CRC Press, Boca Raton, FL 51-112
33. Cox J., and Coulter A. Adjuvants - a classification and review of their mode of action. Vaccine 15 (1997) 248-256
34. Cox J., Coulter A., Macfarlane R., Beezum L., Bates J., Wong T., and Drane D. Development of an influenza-izcom vaccine. Vaccine Design: The Role of Cytokine Networks (1997), Plenum Publishing, New York 33-49
35. Dalsgaard K. Saponin adjuvants III. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. Arch. Ges. Virusforsch. 44 (1974) 243-254
36. Dalsgaard K. A study on the isolation and characterisation of the saponin Quil A. Evaluation of its adjuvant activity with special reference to the application in foot-and-mouth disease. Acta Vet. Scand. 69 (1978) 1-40 SuppL
37. Dalsgaard K. Adjuvants. Vet. Immunol. Immunopathol. 17 (1987) 145-152
38. Dalsgaard K., Hilgers L., and Trouvé G. Classical and new approaches to adjuvant use in domestic animals. Adv. Vet-Sci. Comp. Med. 35 (1990) 121-160
39. Dourmashkin R.R., Dougherty R.M., and Harris R.J. Electron microscopic observation on rous sarcoma virus and cell membranes. Nature 194 (1962) 1116-1119
40. Espinet R.G. Nuevo tipo de vacuna antiafosa a complejo glucovirico. Gac. Vet. 74 (1951) 1-13
41. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., ter Schegget J., Melief C.J., and Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23 (1993) 2242-2249
42. Forsthuber T., Yip H.C., and Lehmann P.V. Induction of Th1 and Th2 immunity in neonatal mice. Science 271 (1996) 1728-1730
43. Fossum C., Bergstrom M., Lövgren K., Watson D.L., and Morein B. Effect of iscom and/or their adjuvant moiety (matrix) on the initial proliferative and IL-2 responses in vitro. Comparison of spleen cells from mice inoculated with iscoms and/or matrix. Cell. Immunol. 129 (1990) 414-425
44. Fukumi H. Effectiveness and untoward reactions of oil adjuvant influenza vaccines. Symp. Ser. Immunobiol., Standard 6 (1967)
45. Glenny A.T., Pope C.G., Waddington H., and Wallas U. Immunological notes XVII to XXIV. J. Pathol. 29 (1926) 31-40
46. Gould-Fogerite S., Edghill-Smith Y., Kheiri M., Wang Z., Das K., Feketova E., Canki M., and Mannio R.J. Lipid matrix-based subunit vaccines: A structure-function approach to oral and parenteral immunization. AIDS Res. Human Retrovirus. 10 (1994) S99-S103 Suppl. 2
47. Hamamoka T., Katz D.H., Bloch K.J., and Benacerraf B. Hapten-specific IgE antibody response in mice. I. Secondary IgE response in irradiated recipients of synergic primed spleen cells. J. Exp. Med. 138 (1973) 306-311
48. Hannant D., Jessett D.M., O'Neill T., Dolby C.A., Cook R.F., and Mumford J.A. Responses of ponies to equid herpesvirus-1 ISCOM vaccination and challenge with virus of the homologous strain. Res. Vet. Sci. 54 (1993) 299-305
49. Hansen D.S., Alievi G., Segura E.L., Carlomagni M., Morein B., and Villacrés-Eriksson M. The flagellar fraction of Trypanosoma cruzi depleted of an immunosuppressive antigen enhances protection to infection and elicits spontaneous T cell responses. Parasit. Immunol. 18 (1996) 607-615
50. Hansen D.S., Villacres-Eriksson M., Åkerblom L., Hellman U., Carlomagno M., and Morein B. An immunoaffinity purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-β-mediated mechanism. Scand. J. Immunol. (1997) in press.
51. Heath A.W., Nyan O., Richards C.E., and Playfair J.H.L. Effects of interferon-γ and saponin on lymphocyte traffic are inversely related to adju-vanticity and enhancement of MHC class II expression. Int. Immunol. 3 (1991) 285-292
52. Henricson B.E., Benjamin W.R., and Vogel S.N. Differential cytokine induction by doses of lipopolysaccaride and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect. Immun. 58 (1990) 2429-2437
53. Hilleman M.R. Critical appraisal of emulsified oil adjuvants to viral vaccines. Progress in Medical Virology 8 (1966), Krager, New York 131-182
54. + T helper cell phenotype development in a T cell receptor-ab-transgenic model. J. Exp. Med. 182 (1995) 1579-1584
55. Howerton D.A., Hunter R.L., Ziegler H.K., and Check I.J. Induction of macrophage la expression in vivo by a synthetic block copolymer, L81. J. Immunol. 144 (1990) 1578-1584
56. Hu J.G., and Kitagawa T. Studies on the optimal immunization schedule of experimental animals. VI. Antigen dose-response of aluminium hydroxide-aided immunization and booster effect under low antigen dose. Chem. Pharm. Bull. 38 (1990) 2775-2779
57. Hunter R.L., and Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of tri-block and octablock copolymers. J. Immunol. 133 (1984) 3167-3175
58. Hunter R.L., and Bennett B. The adjuvant activity of nonionic block polymer surfactants. II. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23 (1986) 287-300
59. Hunter R., Strickland F., and Kézdy F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127 (1981) 1244-1250
60. Hunter R.L., McNichoII J., and Lai A. Mechanism of action of nonionic block polymer adjuvants. AIDS Res. Human Retrovirus. 10 (1994) S95-S98 Suppl. 2
61. Hunter R.L., Olsen M.R., and Bennett B. Copolymer adjuvants and TiterMax. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 51-94
62. *O antigen of Salmonella typhosa. V. Enhancement of antibody responses to protein antigens by the purified lipopolysaccharide. J. Exp. Med. 103 (1956) 225-246
63. Jones G.E., Jones K.A., Machell J., Brebner J., Anderson I.E., and How S. Efficacy trials with tissue-culture grown, inactivated vaccines against chlamydial abortion in sheep. Vaccine 13 (1995) 715-723
64. Jones P.D., Tha Hla R., Morein B., Lövgren K., and Ada G.L. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulating complexes (iscoms. Scand. J. Immunol. 27 (1988) 645-652
65. Kalish M.L., Check I.J., and Hunter R.L. Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite protein (NAGG)5. I. Effects of carrier, copolymer adjuvants and nontoxic LPS on isotype selection. J. Immunol. 146 (1991) 3583-3590
66. Karagouni E.E., and Hadjipetrou-Kourounakis L. Regulation of immunoglobulin production by adjuvants in vivo. Scand. J. Immunol. 31 (1990) 745-754
67. Kenney J.S., Hughes B.W., Masada M.P., and Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Methods 121 (1989) 157-166
68. Kensil C., Patel C., Lennick M., and Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146 (1991) 431-437
69. Kersten G.F.A., and Crommelin D.J.A. Liposomes and iscoms as vaccine formulations. Biochim. Biophys. Acta 1241 (1995) 117-138
70. Kersten G.F.A., Teerlink T., Derks H.J.G.M., Verkleij A.J., van Wesel T.L., Crommelin D.J.A., and Beuvery E.C. Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): chemical analysis, some structural features and comparison of their immuno-genicity with other antigen delivery systems. Infect. Immun. 56 (1988) 432-438
71. Kersten G.F.A., Spiekstra A., Beuvery E.C., and Crommelin D.J.A. On the structure of immune-stimulating saponin-lipid complexes (iscoms. Biochim. Biophys. Acta 1062 (1991) 165-171
72. Kimura J., Nariuchi H., Wantanabe T., Matuhashi T., Okayasu I., and Hatakeyama S. Studies of the adjuvant effect of water-in-oil-in-water (w/o/w) emulsion of sesame oil. I. Enhanced and persistent antibody formation by antigen incorporated into the water-in-oil-in-water emulsion. Jpn. J. Exp. Med. 48 (1978) 149-154
73. Larsson M., Lövgren K., and Morein B. Immunopotentiation of synthetic oligopeptides by chemical conjugation to ISCOMs. J. Immunol. Methods 162 (1993) 257-260
74. Lascelles A.K., Eagleson G., Beh K.J., and Watson D.L. Significance of Freund's adjuvant/antigen injection granuloma in the maintenance of serum antibody response. Vet. Immunol. Immunopathol. 22 (1989) 15-27
75. Lemaire G., Tenu J.-C., and Lacave C.S. Natural and synthetic trehalose diesters as immunomodulators. Med. Res. Rev. 6 (1986) 243-274
76. + cytotoxic T cells. Vaccine 12 (1994) 73-80
77. Lövgren K. The serum antibody responses distributed in subclasses and isotypes following intranasal and subcutaneous immunization with influenza virus iscoms. Scand. J. Immunol. 27 (1988) 241-245
78. Lövgren K., and Larsson M. Conjugation of synthetic peptides to carrier ISCOMs: factors affecting the immunogenicity of the conjugate. J. Immunol. Methods 173 (1994) 237-243
79. Lövgren K., and Morein B. The requirement of lipids for the formation of immunostimulating complexes (iscoms. Biotechnol. Appl. Biochem. 10 (1988) 161-172
80. Lövgren, K. and Sundquist, B. (1994). Comparison of four different adjuvant formulations with two types of antigens; influenza virus protein micelles and oval-bumin. IBC Conference on Novel Vaccine Strategies, Washington, 23--25 February 1994.
81. Lövgren K., Lindmark J., Pipkorn R., and Morein B. Antigenic presentation of small molecules and synthetic peptides conjugated to a preformed iscom as carrier. J. Immunol. Methods 98 (1987) 137-143
82. Lövgren K., Kåberg H., and Morein B. An experimental influenza subunit vaccine (ISCOM) - induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin. Exp. Immunol. 82 (1990) 435-439
83. Lövgren-Bengtsson K., and Sjölander A. Adjuvant activities of iscoms and iscom matrix; two different formulations of Quillaja saponin and antigen. Vaccine 14 (1996) 753-760
84. Lucy J.A., and Glauert A.M. Structure and assembly of macromolecular lipid complexes composed of globular micelles. J. Mol. Biol. 8 (1964) 727-748
85. Ma J., Bulger P.A., Davis D.R., Perilli-Palmer P., Bedore D.A., Kensil C.R., Young E.M., Hung C.H., Seals J.R., and Pavia C.S. Vaccine 12 (1994) 925-932
86. Mannhalter J.W., Neychev H.O., Zlabinger G.J., Ahmad R., and Eibl M.M. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen processing. Clin. Exp. Immunol. 61 (1985) 143-151
87. McLaughlin C.A., Ribi E.E., Goren M.B., and Toubiana R. Tumor regression induced by defined microbial components in an oil-in-water emulsion is mediated through their binding to oil droplets. Cancer Immunol. Immunother. 4 (1978) 109-113
88. Merza M., Linné T., Höglund S., Portetelle D., Burny A., and Morein B. Bovine leukemia virus iscoms: biochemical characterization. Vaccine 7 (1989) 22-28
89. Meyer T.J., Ribi E.E., Azuma I., and Zbar B. Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma. J. Natl Cancer Inst. 52 (1974) 103-111
90. Millet P., Kalish M., Collins W.E., and Hunter R.L. Effect of adjuvant formulation on the selection of B-cell epitopes expressed by a malaria peptide vaccine. Vaccine 10 (1992) 547-550
91. Morein B., Sundquist B., Höglund S., Dalsgaard K., and Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308 (1984) 457-460
92. Morein B., Ekström J., and Lövgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J. Immunol. Methods 128 (1990) 177-181
93. Morein B., Lövgren K., Rönnberg B., Sjölander A., and Villacrés-Eriksson M. Immunostimulating complexes. Clinical potential in vaccine development. Clin. Immunother. 3 (1995) 409-487
94. Morein B., Lövgren-Bengtsson K., and Cox J. Modern adjuvants. Functional aspects. In: Kaufmann S.H.E. (Ed). Concepts in Vaccine Development (1996), Walter de Gruyter, Berlin 243-263
95. Mosmann T.R., and Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7 (1989) 145-173
96. Mowat A.M., Donachie A.M., Reid G., and Jarret O. Immune-stimulating complexes containing Quil A and protein antigen prime class 1 MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route. Immunology 72 (1991) 317-322
97. Mumford J.A., Jesset D., Dunleavy U., Wood J., Hannant D., Sundquist B., and Cook R.F. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 12 (1994) 857-863
98. Mumford J.A., Jesset D., Rollinson E.A., Hannant D., and Draper M.E. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet. Record Feb. 12 (1994) 158-162
99. Murray R., Cohen P., and Hardegree M.C. Mineral oil adjuvants: biological and chemical studies. Ann. Allerg. 30 (1972) 146-151
100. Noll H., Bloch H., Asselineau J., and Lederer E. The chemical structure of the cord factor of Mycobacterium tuberculosis. Biochim. Biophys. Acta 20 (1956) 299-309
101. Nowotny A. Immune reactions elicited or modulated by endotoxin: introduction. In: Nowotny A., Spitzer J.J., and Ziegler E.J. (Eds). Cellular and Molecular Aspects of Endotoxins (1990), Elsevier, Amsterdam 329-338
102. Odean M.V., Frane C.M., Van der Vieren M., Tomai M.A., and Johnson A.G. Involvement of gamma interferon in antibody enhancement by adjuvants. Infect. Immun. 58 (1990) 427-432
103. Ott G., Barchfeld G.L., Chernoff D., Radhakrishnan R., van Hoogevest P., and Van Nest G. Design and evaluation of a safe and potent adjuvant for human vaccines. In: Powell M.F., and Newman M.J. (Eds). Vaccine Design: The Subunit Adjuvant Approach (1995), Plenum Press, New York 277-296
104. Özel M., Höglund S., Gelderblom H., and Morein B. Quaternary structure of the immunostimulating complex (ISCOM. J. Ultrastruct. Mol. Struct. Res. 102 (1989) 240-248
105. Pedersen I.R., Bøg-Hansen T.C., Dalsgaard K., and Heegaard P.M.H. Iscom immunization with synthetic peptides representing measles virus hemagglutinin. Virus Res. 24 (1992) 145-169
106. Phillips N.C., Gagné L., Ivanoff N., and Riveau G. Influence of phospho-lipid composition on antibody response to liposome encapsulated protein and peptide. Vaccine 14 (1996) 898-904
107. Pyle S., Morein B., Bess J., Åkerblom L., Nara P., Nigida S., Lerche N., Fishinger P., and Arthur L. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HIV-1 external envelope glycoprotein. Vaccine 7 (1989) 465-473
108. Ramanathan V.D., Badenoch-Jones P., and Turk J.L. Complement activation by aluminium and zirconium compounds. Immunology 37 (1979) 881-888
109. Ramon G. Precédés pour accroitre la production des antitoxines. Ann. Inst. Pasteur, Paris 40 (1926) 1-10
110. Reid G. Soluble proteins incorporate into iscoms after covalent attachment of fatty acid. Vaccine 10 (1992) 597-602
111. Rietschel E.T., Brade H., Brade L., Kaca W., Kawahara K., Lindner B., Luderitz T., Tomita T., Schade U., and Seydel U. Newer aspects of the chemical structure and biological activity of bacterial endotoxins. Prog. Clin. Biol. Res. 189 (1985) 31-51
112. Ridge J.P., Fuchs E.J., and Matzinger P. Neonatal tolerance revisited: turning on newborn T cells with dendritic cells. Science 271 (1996) 1723-1728
113. Rimmelzwaan G.F., and Osterhaus A.D. A novel generation of viral vaccines based on the ISCOM matrix. Pharm. Biotechnol. 6 (1995) 543-558
114. Rönnberg B., Fekadu M., and Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in iscom-matrix. Vaccine 13 (1995) 1375-1382
115. Rudbach J.A., Johnson D.A., and Ulrich J.T. Ribi adjuvants: chemistry, biology and utility in vaccines for human and veterinary medicine. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 287-313
116. Sarzotti M., Robbins D.S., and Hoffman P.M. Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271 (1996) 1726
117. Scheepers K., and Becht H. Protection of mice against an influenza virus infection by oral vaccination with viral nucleoprotein incorporated into immunostimulating complexes. Med. Microbiol. Immunol. 183 (1994) 265-278
118. Schenck J.R., Hargie M.P., Brown M.S., Ebert D.S., Yoo A.L., and Mclntire F.C. The enhancement of antibody formation by Escherichia coli lipopolysaccaride and detoxified derivative. J. Immunol. 102 (1969) 1411-1422
119. Schumann G., van Hoogevest P., and Frankhauser P. Comparison of free and liposomal MTP-PE: pharmacological, toxicological and pharmakokinetic aspect. In: Lopez-Berestein G., and Fidler I.J. (Eds). Liposomes in the Therapy of Infectious Disease and Cancer (1989), A. R. Liss, New York 191-203
120. Scott M.T., Bahr G., Moddaber F., Afchain D., and Chedid L. Adjuvant requirements for protective immunization of mice using a Trypanosoma cruzi 90 kilodalton cell surface glycoprotein. Int. Arch. Allergy Appl. Immunol. 74 (1984) 373-377
121. Seeber S.J., White J.L., and Hem S.L. Predicting the adsorbtion of proteins by aluminium-containing adjuvants. Vaccine 9 (1991) 201-203
122. Sjölander A., Lövgren K., Ståhl S., Åslund L., Hamsson M., Nygren P.-A., Larsson M., Hagstedt M., Wåhlin B., Berzins K., Uhlén M.L., Morein B., and Perlmann P. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium fald-parum antigen Pfl55/RESA. Vaccine 9 (1991) 443-450
123. Sjölander A., Hansson M., Lövgren K., Wåhlin B., Berzins K., and Perlmann P. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparumantigen Pf 155/RESA. Parasite Immunol. 15 (1993) 355-359
124. Sjölander A., Lövgren-Bengtsson K., Johansson M., and Morein B. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glyco-proteins. Scand. J. Immunol. 43 (1996) 164-172
125. Sjölander S., Hansen J.-E., Lövgren-Bengtsson K., Åkerblom L., and Morein B. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gol20-iscom preparations. A comparison with other adjuvant systems. Vaccine 14 (1996) 344-352
126. Sjölander A., Lövgren-Bengtsson K., and Morein B. Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Vaccine 15 (1997) 1030-1038
127. Sjölander A., van't Land B., and Lövgren-Bengtsson K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell. Immunol. 177 (1997) 69-76
128. Snodgrass D.R., Campbell I., Mwenda J.M., Chege G., Seleman M.A., Morein B., and Hart C.A. Stimulation of rota virus IgA, IgG and neutralising antibodies in baboon milk by parenteral vaccination. Vaccine 13 (1995) 408-413
129. Stewart-Tull D.E.S. Recommendations for the assessment of adjuvants (immunomodulators. In: Gregoriadis G., Allison A.C., and Poste G. (Eds). Immunological Adjuvants and Vaccines (1989), Plenum Press, New York 213-226
130. Stienecker F., Kersten G., van Bloois L., Crommelin D., Hem S., Lower J., and Kreuter J. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13 (1995) 45-53
131. Sundquist B., Lövgren K., and Morein B. Influenza virus iscoms: antibody response in animals. Vaccine 6 (1988) 49-52
132. Takada H., and Kotani S. Structural requirements of lipid A for endotoxi-city and other biological activities. Crit. Rev. Microbiol. 16 (1989) 477-523
133. Takada H., and Kotani S. Muramyl dipeptide and derivatives. In: Stewart-Tull D.E.S. (Ed). The Theory and Practical Application of Adjuvants (1995), Wiley, New York 51-94
134. + cytotoxic T cells by immunization with purified HIV-1 envelope proteins in iscoms. Nature 344 (1990) 873-875
135. Thibault P., and Richou R. Sur l'accroissement de l'immunité antitoxique sous influence de l'addition de diverses substances à l'antigène (anatoxines diphtéroque et tétanique. CR Soc. Biol. 121 (1936) 718-721
136. Uede T., and Ishizaka K. Formation of IgE binding factors by rat T lymphocytes. VI. Cellular mechanisms for the formation of IgE-potentiating factor and IgE-suppressive factor by antigenic stimulation of antigen primed spleen cells. J. Immunol. 129 (1982) 1391-1397
137. Uede T., Huff T.F., and Ishizaka K. Formation of IgE binding factors by rat T lymphocytes. V. Effect of adjuvant for the priming immunization on the nature of IgE binding factors formed by antigenic stimulation. J. Immunol. 129 (1982) 1384-1390
138. Unanue E.R., and Allen P.M. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236 (1987) 551-557
139. Valensi J.P., Carlsson J.R., and Van Nest G.A. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other adjuvants. J. Immunol. 153 (1994) 4029-4039
140. Villacrés-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin. Exp. Immunol. 102 (1995) 46-52
141. Villacrés-Eriksson M., Bergström-Mollauglu M., Kåberg H., and Morein B. Involvement of interleukin-2 and interferon-gamma in the immune response induced by influenza virus iscoms. Scand. J. Immunol. 36 (1992) 421-426
142. Villacrés-Eriksson M., Bergström-Mollauglu M., Kåberg H., Lövgren K., and Morein B. The induction of cell-associated and secreted interleukin-1 by iscoms, matrix or micelles in murine splenic cells. Clin. Exp. Immunol. 93 (1993) 120-125
143. Villacrés-Eriksson M., Behboudi S., Morgan A.I., Trichieri G., and Morein B. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. Cytokine 9 (1997) 73-82
144. Vogel F.R., and Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm. Biotechnol. 6 (1995) 141-228
145. Walls R.S. Eosinophil response to alum adjuvants: involvements of T cells in non-antigen-dependent mechanisms. Proc. Soc. Exp. Biol. Med. 156 (1977) 431-435
146. Watson D.L., Lövgren K., Watson N.A., Fossum Morein C., and Höglund S. The inflammatory response and antigen localization following immunization with influenza virus iscoms. Inflammation 13 (1989) 641-649
147. Watson D., Watson N., Fossum C., Lövgren K., and Morein B. Interactions between immune-stimulating complexes (ISCOMS) and peritoneal mononuclear leucocytes. Microbiol. Immunol. 36 (1992) 199-203
148. Weijer K., Pfauth A., van Herwijnen R., Jarret O., Meloen R.H., Tomee C., and Osterhaus A. Induction of feline leukaemia virus-neutralizing antibodies by peptides derived from the FeLv env gene. Vaccine 11 (1993) 946-956
149. White R.G. The adjuvant effect of microbial products on the immune response. Annu. Rev. Microbiol. 30 (1976) 579-600
150. Woodard L.F. Adjuvant activity of water-insoluble surfactants. Lab. Anim. Sci. 39 (1989) 222-225